BeiGene announces positive regulatory updates in Europe, U.S.

BeiGene announced that the European Commission has approved TEVIMBRA as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma after prior platinum-based chemotherapy. Additionally, the U.S. FDA accepted for review a Biologics License Application for tislelizumab as a first-line treatment for patients with unresectable, recurrent, locally advanced, or metastatic ESCC.